Next-Generation Therapies and Technologies for Immune-Mediated Inflammatory Diseases

Nonfiction, Health & Well Being, Medical, Medical Science, Immunology, Specialties, Pharmacy
Cover of the book Next-Generation Therapies and Technologies for Immune-Mediated Inflammatory Diseases by , Springer International Publishing
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783319422527
Publisher: Springer International Publishing Publication: January 21, 2017
Imprint: Springer Language: English
Author:
ISBN: 9783319422527
Publisher: Springer International Publishing
Publication: January 21, 2017
Imprint: Springer
Language: English

As our understanding of immune mediated chronic inflammatory diseases (IMIDs) grows, it becomes more and more clear that these conditions result from the convergence of a multitude of pathogenic mechanisms whose relative individual contribution is different in different patient subsets.

Promising new technologies have been conceived that address the hypotheses that targeting multiple pathways simultaneously, selectively delivering therapeutics to areas of inflammation and/or resetting the immune system, could take efficacy to new levels. However, we have long waited for the arrival of some of these technologies to the bedside, or even far enough in the drug development process in spite of the initial enthusiasm. Some of the examples covered in this book include bispecific antibodies and genomic medicines, microparticles and targeted delivery of drugs to inflamed vasculature.

Most published reviews and book chapters on novel therapies for inflammatory diseases describe positive attributes of molecules or technologies under investigation and the rationale for developing them into therapeutics. The originality and potential value of this book is not in the description of these targets or technologies from the point of view of their structure or mechanism of action exclusively, but rather, in making an effort to critically address the question of what is needed to move these technologies into the clinic. Has the technology not made it past the preclinical stage and why? Has it already been tested in humans and failed? What are the potential reasons behind those failures? What do experts in each field believe can be done better to increase the probabilities of success?

In addition, the authors address the competitive landscape and summarize clinical studies that have failed in the respective area. They talk about the patient populations that would be required for the successful conduction of a clinical trial to test certain molecules, and they proactively share their views regarding both the potential and the drawbacks of targets or methodologies.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

As our understanding of immune mediated chronic inflammatory diseases (IMIDs) grows, it becomes more and more clear that these conditions result from the convergence of a multitude of pathogenic mechanisms whose relative individual contribution is different in different patient subsets.

Promising new technologies have been conceived that address the hypotheses that targeting multiple pathways simultaneously, selectively delivering therapeutics to areas of inflammation and/or resetting the immune system, could take efficacy to new levels. However, we have long waited for the arrival of some of these technologies to the bedside, or even far enough in the drug development process in spite of the initial enthusiasm. Some of the examples covered in this book include bispecific antibodies and genomic medicines, microparticles and targeted delivery of drugs to inflamed vasculature.

Most published reviews and book chapters on novel therapies for inflammatory diseases describe positive attributes of molecules or technologies under investigation and the rationale for developing them into therapeutics. The originality and potential value of this book is not in the description of these targets or technologies from the point of view of their structure or mechanism of action exclusively, but rather, in making an effort to critically address the question of what is needed to move these technologies into the clinic. Has the technology not made it past the preclinical stage and why? Has it already been tested in humans and failed? What are the potential reasons behind those failures? What do experts in each field believe can be done better to increase the probabilities of success?

In addition, the authors address the competitive landscape and summarize clinical studies that have failed in the respective area. They talk about the patient populations that would be required for the successful conduction of a clinical trial to test certain molecules, and they proactively share their views regarding both the potential and the drawbacks of targets or methodologies.

More books from Springer International Publishing

Cover of the book Applied Mathematics in Tunisia by
Cover of the book New Directions in Music and Human-Computer Interaction by
Cover of the book Machine Learning in VLSI Computer-Aided Design by
Cover of the book Fundamentals of Arc Spraying by
Cover of the book Plant Abiotic Stress Tolerance by
Cover of the book On the Penitentiary System in the United States and its Application to France by
Cover of the book Alcoholic and Non-Alcoholic Fatty Liver Disease by
Cover of the book Media Rich Instruction by
Cover of the book Multi-Agent Based Simulation XVIII by
Cover of the book Male Breast Cancer by
Cover of the book Restorative Justice in China by
Cover of the book Software Engineering: Challenges and Solutions by
Cover of the book Extension of the Fuzzy Sugeno Integral Based on Generalized Type-2 Fuzzy Logic by
Cover of the book Contemporary Oral Oncology by
Cover of the book Software Engineering for Resilient Systems by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy